Amgen (NASDAQ:AMGN – Get Rating) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued on Thursday.

Several other research analysts have also weighed in on AMGN. Barclays boosted their price objective on shares of Amgen from $234.00 to $240.00 and gave the stock an "underweight" rating in a research note on Wednesday, January 18th. Credit Suisse Group initiated coverage on shares of Amgen in a research note on Thursday, November 17th. They set an "underperform" rating and a $240.00 price objective on the stock. Royal Bank of Canada lifted their target price on shares of Amgen from $235.00 to $240.00 and gave the stock a "sector perform" rating in a report on Friday, November 4th. SVB Leerink lifted their target price on shares of Amgen from $256.00 to $282.00 and gave the stock a "market perform" rating in a report on Thursday, December 22nd. Finally, Wells Fargo & Company lifted their target price on shares of Amgen from $250.00 to $285.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 3rd. Four analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $253.57.

Amgen Stock Down 0.5 %

Amgen stock opened at $253.65 on Thursday. The firm has a market capitalization of $135.34 billion, a PE ratio of 20.33, a P/E/G ratio of 1.82 and a beta of 0.67. The company's 50-day moving average is $272.02 and its 200-day moving average is $257.02. Amgen has a fifty-two week low of $214.39 and a fifty-two week high of $296.67. The company has a debt-to-equity ratio of 10.17, a current ratio of 1.68 and a quick ratio of 1.35.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 545 shares of the business's stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $293.54, for a total value of $159,979.30. Following the completion of the sale, the senior vice president now owns 13,009 shares of the company's stock, valued at approximately $3,818,661.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company's stock.

Hedge Funds Weigh In On Amgen

Hedge funds and other institutional investors have recently made changes to their positions in the company. EdgeRock Capital LLC acquired a new position in shares of Amgen in the 3rd quarter valued at approximately $25,000. Leelyn Smith LLC raised its position in shares of Amgen by 80.3% in the 3rd quarter. Leelyn Smith LLC now owns 110 shares of the medical research company's stock valued at $25,000 after buying an additional 49 shares in the last quarter. Capital Wealth Alliance LLC acquired a new position in Amgen during the 2nd quarter worth approximately $26,000. Glassy Mountain Advisors Inc. acquired a new position in Amgen during the 4th quarter worth approximately $26,000. Finally, Coston McIsaac & Partners acquired a new position in Amgen during the 2nd quarter worth approximately $27,000. 75.53% of the stock is currently owned by institutional investors and hedge funds.

About Amgen

(Get Rating)

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Recommended Stories

• Get a free copy of the StockNews.com research report on Amgen (AMGN)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.